Sports Betting Addiction Lawsuit Sports betting addiction lawsuits are being investigated for college students and young adults who developed gambling problems after using apps like FanDuel and DraftKings, alleging that the platforms failed to warn about the addictive nature of their features and marketing practices.
Nitrous Oxide Lawsuit Individuals who suffered harm, or families who lost a loved one after using nitrous oxide products may be eligible for financial compensation through a nitrous oxide lawsuit.
Hair Relaxer Lawsuit Regular exposure to chemicals in hair relaxer may cause uterine cancer, ovarian cancer and other injuries. Women diagnosed with cancer may be eligible for settlement benefits.
Depo-Provera Lawsuit Depo-Provera lawsuits are being investigated for women who developed meningioma brain tumors after receiving Depo-Provera birth control shots, claiming that Pfizer failed to adequately disclose side effects.
Ozempic Lawsuit Lawyers are pursuing Ozempic lawsuits, Wegovy lawsuits and Mounjaro lawsuits over gastroparesis or stomach paralysis, which can leave users with long-term gastrointestinal side effects
Suboxone Tooth Decay Lawsuit Lawsuits are being pursued by users of Suboxone who experienced tooth loss, broken teeth or required dental extractions. Settlement benefits may be available.
Change Healthcare Lawsuit Lawyers are reviewing Change Healthcare class action lawsuits for individuals who had their personal information stolen due to the data breach.
Bard PowerPort Lawsuit Serious and life-threatening injuries have been linked to problems with Bard PowerPort. Lawsuits are now being pursued by individuals who suffered injuries from the implantable port catheter fracturing or migrating.
AngioDynamics Port Catheter Lawsuit Serious and life-threatening injuries have been linked to problems with Bard PowerPort. Lawsuits are now being pursued by individuals who suffered injuries from the implantable port catheter fracturing or migrating.
Processed Food Lawsuit Lawsuits are being pursued against the food industry over their manufacturing and advertising of ultra-processed foods, which have caused a generation of children to face an increased risk of developing childhood diabetes and other chronic illnesses.
U.S. JPML Again Rejects Centralization Request for Withdrawal Lawsuits over Cymbalta October 12, 2015 Austin Kirk Add Your Comments A panel of federal judges has once again rejected a motion seeking to establish consolidated pretrial proceedings for all Cymbalta lawsuits filed by individuals who allege they suffered withdrawal problems following use of the antidepressant. In an order (PDF) issued on Friday, the U.S. Judicial Panel on Multidistrict Litigation (JPML) denied a request to transfer all withdrawal lawsuits over Cymbalta to one judge for coordinated pretrial proceedings. This is the second time the panel has declined to create a federal multidistrict litigation (MDL) for the cases, meaning that at least 41 lawsuits filed on behalf of more than 249 plaintiffs will proceed in various different U.S. District Courts without formal coordination. Do You Know about… SPORTS BETTING ADDICTION LAWSUITS FOR YOUNG ADULTS Gambling addiction and severe financial losses have been linked to popular sports betting platforms like DraftKings, FanDuel, and Caesars. Lawsuits are being filed by young adults and students who were targeted by deceptive promotions, addictive app features, and aggressive marketing tactics. See if you qualify for a sports betting addiction lawsuit. Learn More SEE IF YOU QUALIFY FOR COMPENSATION Do You Know About… SPORTS BETTING ADDICTION LAWSUITS FOR YOUNG ADULTS Gambling addiction and severe financial losses have been linked to popular sports betting platforms like DraftKings, FanDuel, and Caesars. Lawsuits are being filed by young adults and students who were targeted by deceptive promotions, addictive app features, and aggressive marketing tactics. See if you qualify for a sports betting addiction lawsuit. Learn More SEE IF YOU QUALIFY FOR COMPENSATION In December 2014, the panel rejected a similar request to establish a Cymblata MDL for all withdrawal cases, indicating that there were too few lawsuits filed at that time. However, despite an increase in the number of complaints filed over the past year, the panel was still not convinced that centralized management was necessary During oral arguments presented on October 1, plaintiffs argued that the Cymbalta cases should be centralized before one judge to reduce the risk of duplicative discovery into common issues in the cases, avoid conflicting pretrial rulings from different courts and to generally serve the convenience of the parties, witnesses and the judicial system. The U.S. JPML indicates that there has been no “significant change in circumstances” to warrant consolidation at this time, finding that informal coordination among the limited number of unique lawyers involved in the lawsuits remains practicable. “All the factors that weighed against centralization [in December 2014] still are present today,” the panel noted. “These 41 cases are at substantially different procedural stages.” The panel indicates that common discovery has advanced even further since the original decision to deny the requested centralization, pointing out that the drug maker has said this common discovery will be made available to all plaintiffs. At least one Cymbalta withdrawal lawsuit has already gone before a jury, with a trial over the summer in the U.S District Court for the Central District of California ending in a defense verdict. Cymbalta Withdrawal Side Effects Cymbalta (duloxetine) was approved by the FDA in 2004, for the treatment of depression. It is part of a family of drugs known as selective serotonin reuptake inhibitors (SSRIs), which have been linked to symptoms of withdrawal since at least 2001. According to a 2012 report by the Institute for Safe Medication Practices (ISMP), early clinical studies have shown that about half of patients who abruptly discontinued use of Cymbalta suffered withdrawal symptoms. About 10% of those cases involved severe problems and more than half of the cases involved side effects that lasted longer than a week or two. Instead of providing clear information about the risk of serious and potentially severe withdrawal symptoms with Cymbalta, plaintiffs in the lawsuit allege that the medication guide and label provided with the drug provided only a very vague warning. ISMP called the warning “materially deficient,” pointing out that it does not tell patients what to be concerned about, how many patients could be affected, how severe the symptoms could be, and does not tell them the best way of quitting Cymbalta. Eli Lilly told the ISMP that they referred patients to their doctors and pharmacists, but the independent group noted that the information given to doctors did not include withdrawal problems as something to discuss with their patients. Plaintiffs allege that they may have avoided serious injury if the drug maker had provided adequate warnings about the potential side effects of Cymbalta. Tags: Antidepressant, Cymbalta, Eli Lilly More Lawsuit Stories MDL Judge Orders Paraquat Lawsuit Settlement Update By June 11, 2025 May 16, 2025 Teen Gambling Problems Frequently Start With Online Sportsbook Betting: Study May 16, 2025 Court Outlines Requirements for Depo-Provera Lawsuit Proof of Use, Type of Meningioma Tumor May 15, 2025 0 Comments Share Your CommentsFirst Name*Last NameEmail* Shared Comments*This field is hidden when viewing the formI authorize the above comments be posted on this page Yes No Post Comment I authorize the above comments be posted on this page Weekly Digest Opt-In Yes, send me a weekly email with the latest lawsuits, recalls and warnings. Want your comments reviewed by a lawyer?To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.Contact Phone #Alt Phone #Private CommentsNOTE: Providing information for review by an attorney does not form an attorney-client relationship.CAPTCHAGA SourceGA CampaignGA MediumGA ContentGA TermNameThis field is for validation purposes and should be left unchanged. Δ MORE TOP STORIES MDL Judge Orders Paraquat Lawsuit Settlement Update By June 11, 2025 (Posted: today) A federal judge has agreed to stay all case-specific discovery deadlines in Paraquat lawsuits, while the parties work to hammer out a settlement agreement to resolve thousands of claims. MORE ABOUT: PARAQUAT PARKINSON’S DISEASE LAWSUITSParaquat Settlement Reached for Parkinson’s Disease Lawsuits Filed in MDL (04/16/2025)Appeals Court Urged To Reinstate Paraquat Lawsuits Previously Set for Bellwether Trials (02/14/2025)Paraquat Lawsuits Over Parkinson’s Disease Risk Set for Trial in October 2025, April 2026 (01/29/2025) Court Outlines Requirements for Depo-Provera Lawsuit Proof of Use, Type of Meningioma Tumor (Posted: yesterday) As new Depo-Provera lawsuits continue to be filed, the judge presiding over the litigation has established key criteria for establishing proof of Depo-Provera use and medical documentation confirming a meningioma diagnosis. MORE ABOUT: DEPO-PROVERA LAWSUITDepo Shot Lawsuit Filed Over Serious Brain Tumor Injuries (05/07/2025)Lawsuit Alleges Depo-Provera Migraines, Headaches Led to Meningioma Brain Tumor Diagnosis (05/01/2025)Depo-Provera Hearing Loss Lawsuit Filed Over Brain Tumor Side Effects (04/22/2025) BioZorb Implant Lawsuit Alleges Tissue Marker Caused Swelling, Fluid Buildup and Chronic Pain (Posted: 2 days ago) A Massachusetts woman’s injuries from a failed tissue marker that was recently recalled led to the need for physical therapy, according to a BioZorb implant lawsuit. MORE ABOUT: BIOZORB LAWSUITFour Women File BioZorb Lawsuit Over Breast Tissue Marker Failures and Injuries (05/05/2025)Lawsuit Claims BioZorb Marker Caused Chronic Pain, Multiple Surgeries After Lumpectomy (04/14/2025)Four BioZorb Breast Tissue Marker Lawsuits Selected for Bellwether Trials (04/02/2025)
Court Outlines Requirements for Depo-Provera Lawsuit Proof of Use, Type of Meningioma Tumor May 15, 2025
MDL Judge Orders Paraquat Lawsuit Settlement Update By June 11, 2025 (Posted: today) A federal judge has agreed to stay all case-specific discovery deadlines in Paraquat lawsuits, while the parties work to hammer out a settlement agreement to resolve thousands of claims. MORE ABOUT: PARAQUAT PARKINSON’S DISEASE LAWSUITSParaquat Settlement Reached for Parkinson’s Disease Lawsuits Filed in MDL (04/16/2025)Appeals Court Urged To Reinstate Paraquat Lawsuits Previously Set for Bellwether Trials (02/14/2025)Paraquat Lawsuits Over Parkinson’s Disease Risk Set for Trial in October 2025, April 2026 (01/29/2025)
Court Outlines Requirements for Depo-Provera Lawsuit Proof of Use, Type of Meningioma Tumor (Posted: yesterday) As new Depo-Provera lawsuits continue to be filed, the judge presiding over the litigation has established key criteria for establishing proof of Depo-Provera use and medical documentation confirming a meningioma diagnosis. MORE ABOUT: DEPO-PROVERA LAWSUITDepo Shot Lawsuit Filed Over Serious Brain Tumor Injuries (05/07/2025)Lawsuit Alleges Depo-Provera Migraines, Headaches Led to Meningioma Brain Tumor Diagnosis (05/01/2025)Depo-Provera Hearing Loss Lawsuit Filed Over Brain Tumor Side Effects (04/22/2025)
BioZorb Implant Lawsuit Alleges Tissue Marker Caused Swelling, Fluid Buildup and Chronic Pain (Posted: 2 days ago) A Massachusetts woman’s injuries from a failed tissue marker that was recently recalled led to the need for physical therapy, according to a BioZorb implant lawsuit. MORE ABOUT: BIOZORB LAWSUITFour Women File BioZorb Lawsuit Over Breast Tissue Marker Failures and Injuries (05/05/2025)Lawsuit Claims BioZorb Marker Caused Chronic Pain, Multiple Surgeries After Lumpectomy (04/14/2025)Four BioZorb Breast Tissue Marker Lawsuits Selected for Bellwether Trials (04/02/2025)